Brief: Silence Therapeutics Says First Patient Dosed In Gemini II Phase I Clinical Trial For SLN124
29/04/2021 07:56
April 29 (Reuters) - Silence Therapeutics PLC SLN.L :
* SILENCE THERAPEUTICS PLC - FIRST PATIENT DOSED IN GEMINI
II
PHASE I CLINICAL TRIAL FOR SLN124
Source text for Eikon: ID:nRSc9906Wa
Further company coverage: SLN.L
((Reuters.Briefs@thomsonreuters.com ;;))
Recent news on Silence Therapeutics
See all newsBrief: Silence Therapeutics Reports Second Quarter 2025 Financial Results And Recent Business Highlights
Brief: Silence Therapeutics files for stock shelf, size not disclosed
Brief: Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study
Brief: Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study Of Zerlasiran In Patients With Elevated Lipoprotein
Brief: Silence Therapeutics PLC Files For Resale Of Up To 5.71 Million Shares By The Selling Securityholders - SEC Filing